No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GERN240705P5000
- 0.75
- +0.15+25.00%
15min DelayClose Jul 2 16:00 ET
0.75High0.75Low
0.75Open0.60Pre Close1 Volume80 Open Interest5.00Strike Price75.00Turnover0.00%IV-1.92%PremiumJul 5, 2024Expiry Date0.83Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.56Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Wuchan Zhongda Geron Co.,Ltd. (SZSE:002722) Pays A CN¥0.19 Dividend In Just Three Days
Wuchan Zhongda Geron Co.,Ltd. (SZSE:002722) stock is about to trade ex-dividend in 3 days. Typically, the ex-dividend date is one business day before the record date which is the date on which a comp
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 222,660 shares of Geron common stock as
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates.Quantum
Geron Corporation's (NASDAQ:GERN) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 27% Over the Past Week
Geron(GERN.US) Officer Sells US$1.96 Million in Common Stock
$Geron(GERN.US)$ Officer Kapur Anil sold 421.88K shares of common stock on Jun 10, 2024 at an average price of $4.645 for a total value of $1.96 million.Source: Announcement What is statement of chang
Geron(GERN.US) Officer Sells US$1.33 Million in Common Stock
$Geron(GERN.US)$ Officer Feller Faye sold 287.9K shares of common stock on Jun 10, 2024 at an average price of $4.634 for a total value of $1.33 million.Source: Announcement What is statement of chang
Comments
3
Barclays Initiates Coverage On Geron Corporation with Overweight Rating, Announces Price Target of $9.
On June 2, 2024, Barclays initiated coverage of Geron Corporation (NasdaqGS:GERN) with an Overweight rating, setting a price target of $9. At the time of this announcement, Geron’s stock was trading at $4.83, indicating a bullish sentiment from Barclays and predicting significant potential upside for investors. $Geron(GERN.US$
https://stockregion.app/p/investment-bank-initiates-overweight
On June 2, 2024, Barclays initiated coverage of Geron Corporation (NasdaqGS:GERN) with an Overweight rating, setting a price target of $9. At the time of this announcement, Geron’s stock was trading at $4.83, indicating a bullish sentiment from Barclays and predicting significant potential upside for investors. $Geron(GERN.US$
https://stockregion.app/p/investment-bank-initiates-overweight
🚨 1 AdCom & 3 PDUFA decisions this week:
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals(REGN.US$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb(BMY.US$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline(GSK.US$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
9
1
$Geron(GERN.US$
This could get interesting considering the short stats.
2.85 days to cover. 10.46% short floats.
This could get interesting considering the short stats.
2.85 days to cover. 10.46% short floats.
1
Geron Announces FDA Approval of RYTELO™ (Imetelstat) for Lower-Risk MDS with Transfusion-Dependent Anemia.
On June 7, 2024, Geron Corporation, a commercial-stage biopharmaceutical company, proudly announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat), marking a milestone in the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. This ...
On June 7, 2024, Geron Corporation, a commercial-stage biopharmaceutical company, proudly announced that the U.S. Food and Drug Administration (FDA) has approved RYTELO™ (imetelstat), marking a milestone in the treatment of adult patients with lower-risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. This ...
Read more